Phoenix Financial Ltd. Buys 5,852 Shares of Eli Lilly and Company (NYSE:LLY)

Key Points

• Phoenix Financial Ltd. increased its stake in Eli Lilly and Company by 30.7% in Q1, owning a total of 24,889 shares worth around $20.57 million.
• Brokerages have adjusted their price targets for Eli Lilly, with UBS reducing its target from $1,100.00 to $1,050.00 while maintaining a "buy" rating; overall, the stock has a consensus rating of "Moderate Buy".
• Eli Lilly's recent quarterly earnings report showed an EPS of $3.34, falling short of estimates, with revenue up 45.2% compared to the prior year.

Phoenix Financial Ltd. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 30.7% in the first quarter, according to its most recent filing with the SEC. The firm owned 24,889 shares of the company's stock after acquiring an additional 5,852 shares during the quarter. Phoenix Financial Ltd.'s holdings in Eli Lilly and Company were worth $20,572,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of LLY. WestEnd Advisors LLC boosted its position in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the last quarter. Citizens National Bank Trust Department increased its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company during the first quarter worth approximately $40,000. Mascagni Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $43,000. Finally, Prudent Man Investment Management Inc. bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $48,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 0.3%

NYSE:LLY traded up $2.31 during mid-day trading on Monday, hitting $815.00. The company had a trading volume of 1,099,933 shares, compared to its average volume of 3,749,341. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The business's fifty day moving average is $771.95 and its two-hundred day moving average is $800.61. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The firm has a market cap of $772.40 billion, a P/E ratio of 66.29, a P/E/G ratio of 1.18 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter last year, the firm earned $2.58 earnings per share. The business's revenue for the quarter was up 45.2% compared to the same quarter last year. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.74%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 48.82%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. UBS Group decreased their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price target for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Guggenheim boosted their price target on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a research report on Friday, July 11th. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target on the stock. Finally, Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.